1.35

1.47% -0.01

Telomir Pharmaceuticals Inc (TELO)

Overview News Price History Discussions Forecast

Telomir Pharmaceuticals Inc stock is traded at $1.35, with a volume of 115.39K. It is down -1.47% in the last 24 hours and down -10.07% over the past month. Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.

Previous Close:

$1.36

Open:

$1.35

24h Volume:

115.39K

Relative Volume:

0.03

Market Cap:

$43.90M

Revenue:

Net Income/Loss:

$-16.14M

P/E Ratio:

-2.50

EPS:

-0.54

Net Cash Flow:

$-3.99M

1W Performance:

+8.94%

1M Performance:

-10.07%

6M Performance:

-70.74%

1Y Performance:

-77.92%

1-Day Range:

$1.32

$1.36

1-Week Range:

$1.22

$1.45

52-Week Range:

$1.12

$8.40

Telomir Pharmaceuticals Inc Stock (TELO) Company Profile

Name

Telomir Pharmaceuticals Inc

Sector

Healthcare (1153)

Industry

Biotechnology (648)

Phone

786-396-6723

Address

100 SE 2ND ST, MIAMI

Employee

Twitter

Next Earnings Date

2025-09-03

Latest SEC Filings

TELO's Discussions on Twitter

Compare TELO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TELO Telomir Pharmaceuticals Inc	1.36	46.01M	0	-16.14M	-3.99M	-0.54
VRTX Vertex Pharmaceuticals Inc	393.66	101.15B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	455.66	61.07B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	565.69	59.35B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	747.67	46.29B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	331.79	35.69B	3.81B	-644.79M	-669.77M	-6.24

Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-21-25	Initiated	Rodman & Renshaw	Buy

Telomir Pharmaceuticals Inc Stock (TELO) Latest News

06:56 AM

Exit strategy if you’re trapped in Telomir Pharmaceuticals Inc.Market Activity Recap & Verified Entry Point Signals - newser.com

06:56 AM

12:09 PM

Can momentum traders help lift Telomir Pharmaceuticals Inc.Trade Analysis Report & Expert Verified Stock Movement Alerts - newser.com

12:09 PM

12:07 PM

Price momentum metrics for Telomir Pharmaceuticals Inc. explainedPortfolio Return Report & AI Powered Trade Plan Recommendations - newser.com

12:07 PM

Sep 14, 2025

Analyzing recovery setups for Telomir Pharmaceuticals Inc. investorsStop Loss & AI Driven Price Forecasts - newser.com

Sep 14, 2025

Can you recover from losses in Telomir Pharmaceuticals Inc.Earnings Miss & Low Drawdown Trading Techniques - newser.com

Sep 14, 2025

Predicting Telomir Pharmaceuticals Inc. trend using moving averages2025 Top Decliners & Free Low Drawdown Momentum Trade Ideas - newser.com

Sep 14, 2025

Sep 12, 2025

Telomir Pharmaceuticals Stock Price, Quotes and Forecasts - Benzinga

Sep 12, 2025

What high frequency data says about Telomir Pharmaceuticals Inc.2025 Technical Overview & Free Weekly Watchlist of Top Performers - Newser

Sep 12, 2025

Telomir Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 PostEarnings & Long Hold Capital Preservation Tips - Newser

Sep 12, 2025

Backtesting results for Telomir Pharmaceuticals Inc. trading strategiesGap Up & Community Consensus Trade Alerts - Newser

Sep 12, 2025

Short interest data insights for Telomir Pharmaceuticals Inc.Weekly Profit Report & Fast Moving Market Watchlists - Newser

Sep 12, 2025

Analyzing net buyer seller activity in Telomir Pharmaceuticals Inc.Rate Cut & Long-Term Capital Growth Strategies - Newser

Sep 12, 2025

Published on: 2025-09-12 05:33:48 - Newser

Sep 12, 2025

Earnings visualization tools for Telomir Pharmaceuticals Inc.2025 Support & Resistance & High Conviction Buy Zone Picks - Newser

Sep 12, 2025

How high can Telomir Pharmaceuticals Inc. stock goTrade Analysis Summary & Real-Time Price Movement Reports - Newser

Sep 12, 2025

Chart based exit strategy for Telomir Pharmaceuticals Inc.Portfolio Return Summary & Low Risk Growth Stock Ideas - Newser

Sep 12, 2025

Sep 11, 2025

Volume spikes in Telomir Pharmaceuticals Inc. stock – what they meanJuly 2025 Closing Moves & Accurate Technical Buy Alerts - Newser

Sep 11, 2025

Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy - The Florida Times-Union

Sep 11, 2025

Sep 09, 2025

Telomir’s drug candidate shows promise in reversing cancer gene silencing By Investing.com - Investing.com Nigeria

Sep 09, 2025

Telomir’s drug candidate shows promise in reversing cancer gene silencing - Investing.com

Sep 09, 2025